Circulating Maternal Total Cell-Free DNA, Cell-Free Fetal DNA and Soluble Endoglin Levels in Preeclampsia: Predictors of Adverse Fetal Outcome? A Cohort Study

[1]  Marian F MacDorman,et al.  Fetal and Perinatal Mortality: United States, 2013. , 2015, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[2]  A. Shennan,et al.  Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. , 2015, Obstetrics and gynecology.

[3]  K. Nicolaides,et al.  Fetal fraction of cell‐free DNA in maternal plasma in the prediction of spontaneous preterm delivery , 2015, Ultrasound in Obstetrics and Gynecology.

[4]  Amber Samuel,et al.  Can the quantity of cell‐free fetal DNA predict preeclampsia: a systematic review , 2014, Prenatal diagnosis.

[5]  J. Guerrero,et al.  Role of circulating cell-free DNA levels in patients with severe preeclampsia and HELLP syndrome. , 2013, American journal of hypertension.

[6]  James M. Roberts,et al.  Hypertension in Pregnancy: Executive Summary , 2013 .

[7]  S. Drăghici,et al.  Differences and similarities in the transcriptional profile of peripheral whole blood in early and late-onset preeclampsia: insights into the molecular basis of the phenotype of preeclampsiaa , 2013, Journal of perinatal medicine.

[8]  A. Tabor,et al.  Identifying mild and severe preeclampsia in asymptomatic pregnant women by levels of cell‐free fetal DNA , 2013, Transfusion.

[9]  M. Salem,et al.  Plasma circulating cell-free DNA and uteroplacental blood flow in pre-eclamptic patients , 2013 .

[10]  Qinyu Ge,et al.  Quantification of Maternal Serum Cell-Free Fetal DNA in Early-Onset Preeclampsia , 2013, International journal of molecular sciences.

[11]  T. Musci,et al.  Maternal Plasma Cell-Free Fetal and Maternal DNA at 11-13 Weeks' Gestation: Relation to Fetal and Maternal Characteristics and Pregnancy Outcomes , 2013, Fetal Diagnosis and Therapy.

[12]  A. Benian,et al.  Clinical evaluations of cell‐free fetal DNA quantities in pre‐eclamptic pregnancies , 2013, The journal of obstetrics and gynaecology research.

[13]  I. Hösli,et al.  Can detection of late‐onset PE at triage by sflt‐1 or PlGF be improved by the use of additional biomarkers? , 2012, Prenatal diagnosis.

[14]  K. Lim,et al.  Plasma Concentrations of Soluble Endoglin versus Standard Evaluation in Patients with Suspected Preeclampsia , 2012, PloS one.

[15]  S. Daly,et al.  TLR9 Provokes Inflammation in Response to Fetal DNA: Mechanism for Fetal Loss in Preterm Birth and Preeclampsia , 2012, The Journal of Immunology.

[16]  Yves Giguère,et al.  Early Administration of Low-Dose Aspirin for the Prevention of Severe and Mild Preeclampsia: A Systematic Review and Meta-Analysis , 2012, American Journal of Perinatology.

[17]  B. Sibai,et al.  Maternal mortality from preeclampsia/eclampsia. , 2012, Seminars in perinatology.

[18]  François Audibert,et al.  Prevention of Preeclampsia and Intrauterine Growth Restriction With Aspirin Started in Early Pregnancy: A Meta-Analysis , 2010, Obstetrics and gynecology.

[19]  S. Robson,et al.  Predictive Value of Clinical and Laboratory Indices at First Assessment in Women Referred with Suspected Gestational Hypertension , 2010, Hypertension in pregnancy.

[20]  R. Romero,et al.  A subset of patients destined to develop spontaneous preterm labor has an abnormal angiogenic/anti-angiogenic profile in maternal plasma: Evidence in support of pathophysiologic heterogeneity of preterm labor derived from a longitudinal study , 2009, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[21]  R. Romero,et al.  A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia , 2009, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[22]  K. Nicolaides,et al.  First-trimester maternal plasma cell-free fetal DNA and preeclampsia. , 2009, American journal of obstetrics and gynecology.

[23]  J. Gabert,et al.  Total and Fetal Cell-Free DNA Analysis in Maternal Blood as Markers of Placental Insufficiency in Intrauterine Growth Restriction , 2009, Fetal Diagnosis and Therapy.

[24]  John C Chappell,et al.  Local guidance of emerging vessel sprouts requires soluble Flt-1. , 2009, Developmental cell.

[25]  H. Won,et al.  P25.08: How can we counsel the parents of fetuses diagnosed with classical hypoplastic left heart syndrome (HLHS) based on recent data? , 2009 .

[26]  I. Sargent,et al.  Maternal Circulating Levels of Activin A, Inhibin A, sFlt-1 and Endoglin at Parturition in Normal Pregnancy and Pre-Eclampsia , 2009, PloS one.

[27]  Marian F MacDorman,et al.  Fetal and perinatal mortality, United States, 2005. , 2009, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[28]  Mitsuaki Suzuki,et al.  Alteration of Serum Soluble Endoglin Levels after the Onset of Preeclampsia Is More Pronounced in Women with Early-Onset , 2008, Hypertension Research.

[29]  D. Roberts,et al.  The placenta in pre-eclampsia and intrauterine growth restriction , 2008, Journal of Clinical Pathology.

[30]  A. Jeyabalan,et al.  Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia. , 2008, Placenta.

[31]  Wenjiang J. Fu,et al.  The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age , 2008, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[32]  Marian F MacDorman,et al.  Fetal and perinatal mortality, United States, 2004. , 2007, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[33]  H. Stepan,et al.  Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. , 2007, The Journal of clinical endocrinology and metabolism.

[34]  F. Luft.  Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[35]  W. Holzgreve,et al.  Occurrence of Neutrophil Extracellular DNA Traps (NETs) in Pre‐Eclampsia , 2006, Annals of the New York Academy of Sciences.

[36]  S. Calza,et al.  Correlation of fetal DNA levels in maternal plasma with Doppler status in pathological pregnancies , 2006, Prenatal diagnosis.

[37]  G. Burton,et al.  Trophoblastic oxidative stress and the release of cell-free feto-placental DNA. , 2006, The American journal of pathology.

[38]  T. Libermann,et al.  Soluble endoglin contributes to the pathogenesis of preeclampsia , 2006, Nature Medicine.

[39]  W. Holzgreve,et al.  Optimized real-time quantitative PCR measurement of male fetal DNA in maternal plasma. , 2005, Annals of the New York Academy of Sciences.

[40]  R. Romero,et al.  High levels of fetal cell-free DNA in maternal serum: a risk factor for spontaneous preterm delivery. , 2005, American journal of obstetrics and gynecology.

[41]  B. Huppertz,et al.  Fetal cells and cell free fetal nucleic acids in maternal blood: new tools to study abnormal placentation? , 2005, Placenta.

[42]  T. Okai,et al.  Total cell‐free DNA (β‐globin gene) distribution in maternal plasma at the second trimester: a new prospective for preeclampsia screening , 2004, Prenatal diagnosis.

[43]  T. Okai,et al.  β‐globin DNA in maternal plasma as a molecular marker of pre‐eclampsia , 2004, Prenatal diagnosis.

[44]  D. Bianchi.  Circulating fetal DNA: its origin and diagnostic potential-a review. , 2004, Placenta.

[45]  T. Okai,et al.  Cell-free fetal DNA in the plasma of pregnant women with severe fetal growth restriction. , 2003, American journal of obstetrics and gynecology.

[46]  B. Sibai,et al.  Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia. , 2001, American journal of obstetrics and gynecology.

[47]  James J. Walker,et al.  Pre-eclampsia , 2000, The Lancet.

[48]  M. Post,et al.  Inhibition of TGF-beta 3 restores the invasive capability of extravillous trophoblasts in preeclamptic pregnancies. , 1999, The Journal of clinical investigation.

[49]  I. Sargent,et al.  Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. , 1999, Clinical chemistry.

[50]  T K Lau,et al.  Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. , 1998, American journal of human genetics.

[51]  S. Lye,et al.  Endoglin regulates trophoblast differentiation along the invasive pathway in human placental villous explants. , 1997, Endocrinology.

[52]  B. Bax,et al.  Culture of syncytiotrophoblast for the study of human placental transfer. Part I: Isolation and purification of cytotrophoblast. , 1997, Placenta.

[53]  G. Emons,et al.  Cell-free fetal DNA and adverse outcome in low risk pregnancies. , 2013, European journal of obstetrics, gynecology, and reproductive biology.

[54]  L. Hunt,et al.  Quantification of cell free fetal DNA in maternal plasma in normal pregnancies and in pregnancies with placental dysfunction. , 2009, American journal of obstetrics and gynecology.

[55]  M. Kumari,et al.  Variant rs10911021 that associates with coronary heart disease in type 2 diabetes, is associated with lower concentrations of circulating HDL cholesterol and large HDL particles but not with amino acids , 2016, Cardiovascular Diabetology.